

INDEX

CONTENTS		Page No.
<i>Abbreviations</i>		i-ii
<i>List of figures</i>		iii-vii
<i>List of tables</i>		viii-x
<i>Preface</i>		xi-xii
CHAPTER-1: INTRODUCTION		1-16
1.1. Drug: From discovery to development		1-2
1.2. Microbial infections and its overview		2-5
1.3. Cancer and its overview		5-8
1.4. Benzothiazole ring systems and its biological activities		9-14
1.5. Targets for antimicrobial and anticancer drugs		14-16
CHAPTER-2: LITERATURE REVIEW		17-46
2.1. Benzothiazoles: A Promising Lead For Drug Development		17-34
2.1.1. Benzothiazoles as anti- microbial agents		17-23
2.1.2. Benzothiazoles as anti- cancer agents		24-34
2.2. Chemistry of benzothiazoles		35-41
2.3. Benzothiazoles as enzyme and receptor agonists/antagonists		41-43
2.4. Targets for antimicrobial and anticancer drugs		44-46
2.4.1. Glucosamine-6-phosphate synthase (Glc-6-PS): a novel target for antimicrobial agents		44
2.4.2. Epidermal Growth factor Receptor-Tyrosine Kinase (EGFR-TK): a novel target for anticancer agents		45-46
CHAPTER-3: RATIONALE, OBJECTIVE & PLAN OF WORK		47-51
3.1. Rationale & Objective		47-48
3.2. Design of 2-(4-aminophenyl)benzothiazole derivatives		49-50
3.3. Plan of work		51

4.1. General procedure for the synthesis of Benzothiazole Schiff base derivatives	52-54
4.2. General procedure for the synthesis of Benzothiazole Amide derivatives	54-56
4.3. General procedure for the synthesis of Benzothiazole 4-thiazolidinones derivatives	56-57
4.4. General procedure for the synthesis of Benzothiazole Oxime and Hydrazone derivatives	57-58
4.5. General procedure for the synthesis of Benzothiazole Semicarbazone and Thiosemicarbazone derivatives	58-61
4.6. Physicochemical and Spectroscopic characterization	61-62
4.7. <i>In-Vitro</i> Antimicrobial Activity Evaluation	63-65
4.7.1. Agar disc Diffusion method	63
4.7.2. Mechanism of action study	64-65
4.7.2.1. Bactericidal kinetics	64
4.7.2.2. Membrane Depolarization assay	64
4.7.2.3. Fluorescence assisted cell sorting (FACS) study	64-65
4.7.2.4. DNA binding assay	65
4.8. <i>In-Vitro</i> Anticancer Activity Evaluation	65-68
4.8.1. MTT assay	66
4.8.2. Mechanism of action study	66-68
4.8.2.1. Immunoblot analysis	66-67
4.8.2.2. Cell cycle study	67
4.8.2.3. Apoptosis assay	67-68
4.8.2.4. DNA fragmentation	68
4.9. Molecular Docking study	68-70
4.9.1. Glucosamine-6-phosphate synthase (Glc-6-PS)	69
4.9.2. Epidermal Growth Factor Receptor- Tyrosine Kinase (EGFR-TK)	70
4.10. <i>In-Silico</i> Pharmacokinetic Predictions	70

CHAPTER-5: RESULTS AND DISCUSSION	71-185
5.1. SERIES-1: Schiff bases of 2-(4-aminophenyl)benzothiazole i.e., 4-arylidine/cycloalkylidene-benzenamine benzothiazole.	71-108
5.1.1. Background	71
5.1.2. Chemistry	71-72
5.1.3. Physicochemical and Spectral Characterization data	72-80
5.1.4. <i>In-vitro</i> antimicrobial activity	81-91
5.1.4.1. Mechanism of action study	83-87
5.1.4.2. Docking study against Glc-6-PS	88-90
5.1.4.3. <i>In-Silico</i> Pharmacokinetic Predictions	90-91
5.1.5. <i>In-vitro</i> anticancer activity	92-108
5.1.5.1. Cytotoxicity study against ovarian cancer cell lines	92-96
5.1.5.2. Cytotoxicity assessment on the basis of selectivity index	96
5.1.5.3. Combinatorial treatment approach	97-98
5.1.5.4. Docking study against EGFR-TK	98-106
5.1.5.5. Immunoblot analysis	106-108
5.2. SERIES-2: Amide derivatives of 2-(4-aminophenyl) benzothiazole i.e., Benzamide analogues	109-134
5.2.1. Background	109
5.2.2. Chemistry	109-110
5.2.3. Physicochemical and Spectral Characterization data	110-113
5.2.4. <i>In-vitro</i> antimicrobial activity	114-122
5.2.4.1. Mechanism of action study	116-121
5.2.4.2. Docking study against Glc-6-PS	121-122
5.2.4.3. <i>In-Silico</i> Pharmacokinetic Predictions	122
5.2.5. <i>In-vitro</i> anticancer activity	123-134
5.2.5.1. Cytotoxicity study against cervical cancer cell lines	123-126
5.2.5.2. Cytotoxicity assessment on the basis of selectivity index	127
5.2.5.3. Cell cycle study	127-129
5.2.5.4. Apoptosis assay	130-132
5.2.5.5. DNA fragmentation	133-134

5.3. SERIES-3: 4-Thiazolidinone derivatives of 4-arylidine-benzenamine benzothiazole	135-148
5.3.1. Background	135
5.3.2. Chemistry	135
5.3.3. Physicochemical and Spectral Characterization data	136-140
5.3.4. <i>In-vitro</i> antimicrobial activity	140-148
5.3.4.1. Mechanism of action study	143-146
5.3.4.2. Docking study against Glc-6-PS	146-148
5.3.4.3. <i>In-Silico</i> Pharmacokinetic Predictions	148
5.4. SERIES-4: Oxime and Hydrazone derivatives of Benzamide analogues	149-158
5.4.1. Background	149
5.4.2. Chemistry	149
5.4.3. Physicochemical and Spectral Characterization data	150-151
5.4.4. <i>In-vitro</i> antimicrobial activity	152-158
5.4.4.1. Mechanism of action study	153-156
5.4.4.2. Docking study against Glc-6-PS	156-157
5.4.4.3. <i>In-Silico</i> Pharmacokinetic Predictions	158
5.5. SERIES-5: Semicarbazone and Thiosemicarbazone derivatives of Benzamide analogues	159-185
5.5.1. Background	159
5.5.2. Chemistry	159
5.5.3. Physicochemical and Spectral Characterization data	160-168
5.5.4. <i>In-vitro</i> antimicrobial activity	169-185
5.5.4.1. Mechanism of action study	172-180
5.5.4.2. Docking study against Glc-6-PS	180-184
5.5.4.3. <i>In-Silico</i> Pharmacokinetic Predictions	185
CHAPTER-6: SUMMARY AND CONCLUSION	186-192

BIBLIOGRAPHY

193-210

List of Publications

List of papers presented in conferences

Reprints of papers published

Candidate's Personal Profile